Persistent culture-positive Legionella infection in an immunocompetent adult.

expected to cause respiratory system infections, including lung abscess [9, 10]. This makes moxifloxacin a highly effective drug for bacterial eradication, and its efficacy has been demonstrated in several clinical trails in patients with community acquired respiratory system infections [9, 10]. Additional advantage of moxifloxacin is once daily administration, which translates to better patient adherence to therapy, and the low propensity for drug interactions [9, 10]. To our knowledge this is the first study showing the utility of moxifloxacin for treatment of lung abscess. We conclude that moxifloxacin is a safe and effective treatment of lung abscess. Excellent oral bioavailability and once daily dosing make it very attractive option for long-term management of lung abscess. Additional prospective studies are required to validate these data.